1
|
Cooper SM, White AJP, Eykyn TR, Ma MT, Miller PW, Long NJ. N-Centered Tripodal Phosphine Re(V) and Tc(V) Oxo Complexes: Revisiting a [3 + 2] Mixed-Ligand Approach. Inorg Chem 2022; 61:8000-8014. [PMID: 35544683 PMCID: PMC9131457 DOI: 10.1021/acs.inorgchem.2c00693] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
![]()
N-Triphos derivatives
(NP3R, R = alkyl, aryl)
and asymmetric variants (NP2RXR′, R′ = alkyl, aryl, X = OH, NR2, NRR′) are
an underexplored class of tuneable, tripodal ligands in relation to
the coordination chemistry of Re and Tc for biomedical applications.
Mixed-ligand approaches are a flexible synthetic route to obtain Tc
complexes of differing core structures and physicochemical properties.
Reaction of the NP3Ph ligand with the Re(V)
oxo precursor [ReOCl3(PPh3)2] generated
the bidentate complex [ReOCl3(κ2-NP2PhOHAr)], which possesses an unusual
AA’BB’XX’ spin system with a characteristic second-order
NMR lineshape that is sensitive to the bi- or tridentate nature of
the coordinating diphosphine unit. The use of the asymmetric NP2PhOHAr ligand resulted in the formation
of both bidentate and tridentate products depending on the presence
of base. The tridentate Re(V) complex [ReOCl2(κ3-NP2PhOAr)] has provided
the basis of a new reactive “metal-fragment” for further
functionalization in [3 + 2] mixed-ligand complexes. The synthesis
of [3 + 2] complexes with catechol-based π-donors could also
be achieved under one-pot, single-step conditions from Re(V) oxo precursors.
Analogous complexes can also be synthesized from suitable 99Tc(V) precursors, and these complexes have been shown to exhibit
highly similar structural properties through spectroscopic and chromatographic
analysis. However, a tendency for the {MVO}3+ core to undergo hydrolysis to the {MVO2}+ core has been observed both in the case of M = Re and markedly
for M = 99Tc complexes. It is likely that controlling this
pathway will be critical to the generation of further stable Tc(V)
derivatives. An N-centered tripodal heterofunctionalized
phosphine ligand
was used to generate a reactive “metal-fragment” based
on the {MVO}3+ (M = Re, 99Tc) core
for the formation of mixed-ligand [3 + 2] complexes. Characteristic
lineshapes arising from an AA’BB’XX’ spin system
are diagnostic of bidentate vs tridentate coordination modes of the
ligand.
Collapse
Affiliation(s)
- Saul M Cooper
- Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, 82 Wood Lane, White City Campus, London W12 0BZ, UK.,School of Biomedical Engineering & Imaging Sciences, King's College London, 4th Floor Lambeth Wing, St Thomas' Hospital, London SE1 7EH, UK
| | - Andrew J P White
- Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, 82 Wood Lane, White City Campus, London W12 0BZ, UK
| | - Thomas R Eykyn
- School of Biomedical Engineering & Imaging Sciences, King's College London, 4th Floor Lambeth Wing, St Thomas' Hospital, London SE1 7EH, UK
| | - Michelle T Ma
- School of Biomedical Engineering & Imaging Sciences, King's College London, 4th Floor Lambeth Wing, St Thomas' Hospital, London SE1 7EH, UK
| | - Philip W Miller
- Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, 82 Wood Lane, White City Campus, London W12 0BZ, UK
| | - Nicholas J Long
- Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, 82 Wood Lane, White City Campus, London W12 0BZ, UK
| |
Collapse
|
2
|
Kręcisz P, Czarnecka K, Królicki L, Mikiciuk-Olasik E, Szymański P. Radiolabeled Peptides and Antibodies in Medicine. Bioconjug Chem 2020; 32:25-42. [PMID: 33325685 PMCID: PMC7872318 DOI: 10.1021/acs.bioconjchem.0c00617] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
![]()
Radiolabeled peptides
are a relatively new, very specific radiotracer
group, which is still expanding. This group is very diverse in terms
of peptide size. It contains very small structures containing several
amino acids and whole antibodies. Moreover, radiolabeled peptides
are diverse in terms of the binding aim and therapeutic or diagnostic
applications. The majority of this class of radiotracers is utilized
in oncology, where the same structure can be used in therapy and diagnostic
imaging by varying the radionuclide. In this study, we collected new
reports of radiolabeled peptide applications in diagnosis and therapy
in oncology and other fields of medicine. Radiolabeled peptides are
also increasingly being used in rheumatology, cardiac imaging, or
neurology. The studies collected in this review concern new therapeutic
and diagnostic procedures in humans and new structures tested on animals.
We also performed an analysis of clinical trials, which concerns application
of radiolabeled peptides and antibodies that were reported in the
clinicaltrials.gov database between 2008 and 2018.
Collapse
Affiliation(s)
- Paweł Kręcisz
- Department of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland
| | - Kamila Czarnecka
- Department of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland
| | - Leszek Królicki
- Department of Nuclear Medicine, Medical University of Warsaw, ul. Banacha 1 a, 02-097, Warsaw, Poland
| | - Elżbieta Mikiciuk-Olasik
- Department of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland
| | - Paweł Szymański
- Department of Pharmaceutical Chemistry, Drug Analyses and Radiopharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Lodz, Poland
| |
Collapse
|
3
|
Southworth R, Torres Martin de Rosales R, Meszaros LK, Ma MT, Mullen GED, Fruhwirth G, Young JD, Imberti C, Bagunya-Torres J, Andreozzi E, Blower PJ. Opportunities and challenges for metal chemistry in molecular imaging: from gamma camera imaging to PET and multimodality imaging. ADVANCES IN INORGANIC CHEMISTRY 2015; 68:1-41. [PMID: 30381783 PMCID: PMC6205628 DOI: 10.1016/bs.adioch.2015.09.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The development of medical imaging is a highly multidisciplinary endeavor requiring the close cooperation of clinicians, physicists, engineers, biologists and chemists to identify capabilities, conceive challenges and solutions and apply them in the clinic. The chemistry described in this article illustrates how synergistic advances in these areas drive the technology and its applications forward, with each discipline producing innovations that in turn drive innovations in the others. The main thread running through the article is the shift from single photon radionuclide imaging towards PET, and in turn the emerging shift from PET/CT towards PET/MRI and further, combination of these with optical imaging. Chemistry to support these transitions is exemplified by building on a summary of the status quo, and recent developments, in technetium-99m chemistry for SPECT imaging, followed by a report of recent developments to support clinical application of short lived (Ga-68) and long-lived (Zr-89) positron emitting isotopes, copper isotopes for PET imaging, and combined modality imaging agents based on radiolabelled iron oxide based nanoparticles.
Collapse
Affiliation(s)
- Richard Southworth
- King's College London, Division of Imaging Sciences and Biomedical Engineering, St Thomas' Hospital, London, UK
| | | | - Levente K Meszaros
- King's College London, Division of Imaging Sciences and Biomedical Engineering, St Thomas' Hospital, London, UK
| | - Michelle T Ma
- King's College London, Division of Imaging Sciences and Biomedical Engineering, St Thomas' Hospital, London, UK
| | - Gregory E D Mullen
- King's College London, Division of Imaging Sciences and Biomedical Engineering, St Thomas' Hospital, London, UK
| | - Gilbert Fruhwirth
- King's College London, Division of Imaging Sciences and Biomedical Engineering, St Thomas' Hospital, London, UK
| | - Jennifer D Young
- King's College London, Division of Imaging Sciences and Biomedical Engineering, St Thomas' Hospital, London, UK
| | - Cinzia Imberti
- King's College London, Division of Imaging Sciences and Biomedical Engineering, St Thomas' Hospital, London, UK
| | - Julia Bagunya-Torres
- King's College London, Division of Imaging Sciences and Biomedical Engineering, St Thomas' Hospital, London, UK
| | - Erica Andreozzi
- King's College London, Division of Imaging Sciences and Biomedical Engineering, St Thomas' Hospital, London, UK
| | - Philip J Blower
- King's College London, Division of Imaging Sciences and Biomedical Engineering, St Thomas' Hospital, London, UK
| |
Collapse
|
4
|
Tavaré R, Williams J, Howland K, Blower PJ, Mullen GED. [Re(CO)(3)](+) labelling of a novel cysteine/hexahistidine tag: insights into binding mode by liquid chromatography-mass spectrometry. J Inorg Biochem 2012; 114:24-7. [PMID: 22687562 DOI: 10.1016/j.jinorgbio.2012.04.006] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2012] [Revised: 04/13/2012] [Accepted: 04/20/2012] [Indexed: 11/28/2022]
Abstract
We recently described a novel amino acid sequence, KCKLAAALEHHHHHH, for site-specific radiolabelling of proteins with [(99m)Tc(CO)(3)(OH(2))(3)](+) or [Re(CO)(3)(OH(2))(3)](+) with improved efficiency compared to conventional hexahistidine tags (His-tag). C2AH, a modification of the protein C2A (the phosphatidylserine (PS)-binding domain of rat synaptotagmin I) engineered to contain this novel C-terminal tag, was produced. Rhenium tricarbonyl conjugates of C2AH were analysed post tryptic digest by liquid chromatography-electrospray mass spectrometry (LC-MS), giving rise to a peak with the molecular weight corresponding to M(+)=[Re(CO)(3)+CK+LAAALEHHHHHH](+). This species arises as a result of trypsin cleavage on the C-terminus of both the lysine (Lys) residues on either side of the Cys while both fragments still remain bound to the rhenium. This confirmed that cysteine (Cys) was directly involved in the coordination of the rhenium tricarbonyl. To demonstrate the superiority of the cysteine containing His-tag sequences for binding [Re(CO)(3)](+), two peptides CKLAAALEHHHHHH and LAAALEHHHHHH were synthesised. In a competition experiment the mixed peptides were incubated with one molar equivalent of [Re(CO)(3)(H(2)O)(3)](+), and LC-ESMS demonstrated that 92% and 9% of CKLAAALEHHHHHH and LAAALEHHHHHH respectively were co-ordinated by one [Re(CO)(3)](+).
Collapse
Affiliation(s)
- Richard Tavaré
- Division of Imaging Sciences and Biomedical Engineering, King's College London, St. Thomas' Hospital, London SE1 7EH, UK
| | | | | | | | | |
Collapse
|
5
|
Abstract
The specialised medical field of Nuclear Medicine is concerned with the use of unsealed sources of radioactivity either to diagnose or treat a range of diseases. In this regard it can be distinguished from the field of Radiotherapy which uses sealed radioactive sources for treatment. The range of diseases in which Nuclear Medicine plays a role is wide and includes, among others, the fields of microbiology, endocrinology, neurology, oncology and cardiovascular medicine. However, cancer probably represents the most important and growing area of application for this modality. Nuclear Medicine employs radiopharmaceuticals. These are radiolabelled ligands that have the ability to interact with molecular targets that are relevant in the aetiology or treatment of cancer and in many respects Nuclear Medicine can be considered the archetype for the application of 'Molecular Medicine'. An example of a Nuclear Medicine Positron Emission Tomography (PET) scan is shown in Fig. 2. There is great interest in developing new radioligands that allow us to image the expression of the ever increasing range of biological pathways being discovered in the post-genomic area. Designing effective radiopharmaceuticals, however, requires an understanding of a number of radiopharmaceutical sciences including aspects of chemistry, physics, cell and molecular biology, and physiology.
Collapse
Affiliation(s)
- Stephen J Mather
- Centre for Cancer Imaging and Queen Mary School of Medicine and Dentistry, St Bartholomew's Hospital, London EC1A 7BE, UK.
| |
Collapse
|
6
|
Blower P. Towards molecular imaging and treatment of disease with radionuclides: the role of inorganic chemistry. Dalton Trans 2006:1705-11. [PMID: 16568178 DOI: 10.1039/b516860k] [Citation(s) in RCA: 96] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Molecular imaging and radiotherapy using radionuclides is a rapidly expanding field of medicine and medical research. This article highlights the development of the role of inorganic chemistry in designing and producing the radiopharmaceuticals on which this interdisciplinary science depends.
Collapse
Affiliation(s)
- Phil Blower
- Imaging Sciences, King's College London 5th Floor, Thomas Guy House Guy's Hospital, London, UK SE1 9RT.
| |
Collapse
|